journal article·2010-02

In vivo and in vitro characterization of poly(styrene‐b‐isobutylene‐b‐styrene) copolymer stent coatings for biostability, vascular compatibility and mechanical integrity

Fred Strickler, Robert Richard, Sharon McFadden, Jeff Lindquist, Marlene C. Schwarz, Rudolf Faust, Gregory J. Wilson, Mark Boden

Publisher page

Abstract

Abstract The TAXUS® Express 2™Paclitaxel Eluting Coronary Stent System employs a coating consisting of the thermoplastic elastomer, poly(styrene‐b‐isobutylene‐b‐styrene; SIBS), selected for its drug‐eluting characteristics, vascular compatibility, mechanical properties, and biostability. This study was conducted to evaluate the impact of different SIBS (17−51 mole % styrene) compositions on mechanical properties, chemical stability, and vascular compatibility. Mechanical property (stress−strain measurements) and stability studies were conducted on polymer films with five different styrene contents (17, 24, 32, 39, and 51 mole %). The ultimate tensile strength did not change significantly with composition, but the elongation at break decreased with increased styrene content. A pulsatile fatigue test further confirmed the mechanical stability of SIBS up to 39 mole % styrene. The vascular compatibility of five different SIBS compositions was assessed using SIBS‐only coated stents, in the coronary and carotid arteries in a porcine model study. The stability of the vessel wall, rate/degree of endothelialization, inflammation, and thrombus at timepoints from 30 to 180 days were evaluated. The results confirm vascular compatibility over the range of 17−51 mole % styrene. © 2009 Wiley Periodicals, Inc. J Biomed Mater Res, 2010
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Coronary Interventions and Diagnostics · Cardiac Valve Diseases and Treatments · Cardiac and Coronary Surgery Techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (22)

Show source-provided references
1. 10.1056/NEJMoa03244110.1056/NEJMoa032441 ↗
2. 10.1161/01.CIR.0000038982.49640.7010.1161/01.CIR.0000038982.49640.70 ↗
3. TAXUS® Express2® Paclitaxel‐eluting coronary stent system directions for use 90328768–01 Boston Scientific Corporation.
4. Cypher Sirolimus‐eluting Coronary Stent OTW and RX Instuctions for Use (Rev 9) 10056733‐8 Cordis: a Johnson and Johnson Company.
5. 10.1161/01.CIR.0000127129.94129.6F10.1161/01.CIR.0000127129.94129.6F ↗
6. ShanleyJF EiglerNL. Expandable medical device for delivery of beneficial agent U.S. Patent Application 20 040 254 635 December 2004.
7. 10.4161/cc.3.8.98610.4161/cc.3.8.986 ↗
8. 10.1016/j.addr.2006.01.02310.1016/j.addr.2006.01.023 ↗
9. 10.1002/jbm.a.3018810.1002/jbm.a.30188 ↗
10. 10.1016/0032-3861(96)89388-810.1016/0032-3861(96)89388-8 ↗
11. 10.1016/B978-012582460-6/50002-510.1016/B978-012582460-6/50002-5 ↗
12. Williams DF · 1990
13. PinchukL. Biostable elastomeric polymers having quaternary carbons U.S. Patent 5 741 331 April 1998.
14. Pinchuk L · 2000 · 1452
15. 10.1021/bm034513k10.1021/bm034513k ↗
16. 10.1097/00019501-200409000-0000310.1097/00019501-200409000-00003 ↗
17. 10.1161/01.CIR.94.7.169010.1161/01.CIR.94.7.1690 ↗
18. 10.1161/01.CIR.0000033485.20594.6F10.1161/01.CIR.0000033485.20594.6F ↗
19. 10.1080/1060132920805218910.1080/10601329208052189 ↗
20. 10.1016/j.cardiores.2007.07.00410.1016/j.cardiores.2007.07.004 ↗
21. 10.1080/1060132940935011910.1080/10601329409350119 ↗
22. In vitro and in vivo evaluation of the safety and stability of the TAXUS® paclitaxel‐eluting coronary stent